封面
市場調查報告書
商品編碼
1741312

胰島素拮抗劑市場按胰島素拮抗劑類型、適應症、給藥途徑、通路和地區分類

Insulin Sensitizers Market, By Type of Insulin Sensitizers, By Indication, By Route of Administration, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

胰島素拮抗劑市場規模預計在 2025 年為 237.7 億美元,預計到 2032 年將達到 367 億美元,2025 年至 2032 年的年複合成長率(CAGR)為 6.4%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 237.7億美元
效能數據 2020-2024 預測期 2025-2032
預測期間:2025年至2032年的年複合成長率 6.40% 2032年價值預測 367億美元

胰島素拮抗劑是改善胰島素敏感性並降低血糖值的藥物。它們也被稱為降血糖藥或降血糖藥,有助於在不使用胰島素的情況下將血糖值恢復到正常範圍。它們透過提高肝臟、肌肉和脂肪細胞對胰島素的敏感性來發揮作用。胰島素拮抗劑有多種類型,包括Metformin(Met)、PIOGLITAZONE(Pio)、噻唑烷二酮 (TZD) 和肌醇。

市場動態

全球胰島素拮抗劑市場的成長是由糖尿病,特別是第 2 型糖尿病的盛行率不斷上升所驅動。胰島素拮抗劑經常用於治療第 2 型糖尿病,以增強胰島素敏感性和控制血糖值。肥胖會顯著增加第 2 型糖尿病和胰島素抗性。由於全球肥胖盛行率不斷上升,有效的胰島素拮抗劑可以幫助控制胰島素阻抗和相關代謝疾病。正在進行的研究和開發活動正在產生創新的化合物和製劑,推出新的和增強的胰島素拮抗劑,以提高治療胰島素敏感性藥物的有效性和安全性。此外,各國政府正採取多項舉措來對抗糖尿病。計劃和方案的重點是傳播有關糖尿病的知識、早期發現糖尿病以及推廣必要且負擔得起的治療方法,如胰島素拮抗劑。

與任何藥物一樣,胰島素拮抗劑也存在潛在的副作用,包括體重增加、體液儲存、骨折以及心臟衰竭風險增加。某些類型的胰島素拮抗劑,例如噻唑烷二酮類藥物 (TZD),可能引發安全性問題,從而限制了其使用和廣泛接受。

研究的主要特點

  • 本報告對全球胰島素拮抗劑市場進行了詳細分析,並以 2024 年為基準年,給出了預測期 2025-2032 的市場規模和年複合成長率(CAGR%)。
  • 它還強調了各個領域的潛在商機,並說明了該市場的引人注目的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
  • 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數,介紹了全球胰島素拮抗劑市場的主要企業概況。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 全球胰島素拮抗劑市場報告針對該行業的各個相關人員,例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
  • 相關人員將透過全球胰島素拮抗劑市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • 一致的機會圖(COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 驅動程式
  • 糖尿病盛行率不斷上升
  • 全球肥胖症疫情日益嚴重
  • 藥物研發進展
  • 政府的積極舉措
    • 限制因素
  • 副作用和安全問題
  • 在某些患者族群中療效有限
  • 監管挑戰和市場進入
    • 機會
  • 新興經濟體
  • 個人化醫療
  • 聯合治療
  • 非糖尿病應用
  • 影響分析
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • 波特分析
  • 併購場景

4. 全球胰島素拮抗劑市場-冠狀病毒(COVID-19)大流行的影響

  • COVID-19流行病學
  • 供需側分析
  • 經濟影響

5. 2020 年至 2032 年全球胰島素拮抗劑市場(按胰島素拮抗劑類型)

  • 介紹
  • 胰島素增敏劑(TZD)
  • 雙胍類
  • Incretin-based的治療方法
  • 其他

6. 全球胰島素拮抗劑市場(依適應症分類),2020 年至 2032 年

  • 介紹
  • 2型糖尿病
  • 糖尿病前期
  • 卵巢症候群(PCOS)

7. 2020-2032 年全球胰島素拮抗劑市場(依給藥途徑)

  • 介紹
  • 口服
  • 注射

8. 全球胰島素拮抗劑市場(依分銷管道分類),2020-2032 年

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

9. 全球胰島素拮抗劑市場(按地區分類),2020-2032 年

  • 介紹
  • 北美洲
      • 美國
      • 加拿大
  • 歐洲
      • 英國
      • 德國
      • 義大利
      • 法國
      • 西班牙
      • 俄羅斯
      • 其他歐洲國家
  • 亞太地區
      • 中國
      • 印度
      • 日本
      • 東南亞國協
      • 澳洲
      • 韓國
      • 其他亞太地區
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 中東和非洲
      • 海灣合作理事會國家
      • 以色列
      • 北非
      • 中部非洲
      • 其他中東和非洲地區

第10章 競爭格局

  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical

第 11 章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6069

Insulin Sensitizers Market is estimated to be valued at USD 23.77 Bn in 2025 and is expected to reach USD 36.7 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 23.77 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.40% 2032 Value Projection: USD 36.7 Bn

Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.

Market Dynamics

Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.

Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.

Key features of the study:

  • This report provides in-depth analysis of the global insulin sensitizers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin sensitizers market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global insulin sensitizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin sensitizers market

Insulin Sensitizers Market Detailed Segmentation:

  • By Type:
    • Thiazolidinediones (TZDs)
    • Biguanides
    • Incretin-based therapies
    • Others
  • By Indication:
    • Type 2 Diabetes
    • Prediabetes
    • Polycystic Ovary Syndrome (PCOS)
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Eli Lilly and Company
    • Novo Nordisk
    • Sanofi
    • Merck & Co.
    • Bristol Myers Squibb
    • AstraZeneca
    • Boehringer Ingelheim
    • Johnson & Johnson
    • Takeda Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Insulin Sensitizers
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of diabetes
  • Growing global obesity epidemic
  • Advancements in drug development
  • Favorable government initiatives
    • Restraints
  • Adverse effects and safety concerns
  • Limited efficacy in certain patient populations
  • Regulatory challenges and market access
    • Opportunities
  • Emerging economies
  • Personalized medicine
  • Combination therapies
  • Non-diabetic applications
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Insulin Sensitizers Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Insulin Sensitizers Market, By Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Thiazolidinediones (TZDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Biguanides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Incretin-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Insulin Sensitizers Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Type 2 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn )
  • Prediabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Polycystic Ovary Syndrome (PCOS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Insulin Sensitizers Market, By Route of Administration, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Insulin Sensitizers Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Insulin Sensitizers Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • GCC
      • Israel
      • North Africa
      • Central Africa
      • Rest of Middle East & Africa

10. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us